* blood oxygen saturation level (spo2) \< 94%. * known hypersensitivity to investigational products * chronic treatment with inhaled corticosteroids (up to 30 days) * known history of renal or hepatic failure * abnormal physical examination findings: * respiratory rate \< 25 per minute; * clinical hypotension with associated signs justifying hospital care * feeling unwell for more than 7 days prior to screening. * end-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy \< 3 months. * for any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or intake of concomitant medication proscribed with its use. * patients with known suicidal thoughts, severe psychiatric disorders or major depression that is uncontrolled or controlled by one of the prohibited drugs * known history of long qt syndrome or severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with recovered ventricular fibrillation) * unwilling or unable to comply with the requirements of the study protocol at any time during the study, e.g. no access to or not comfortable with use of a smartphone or with answering questions using a telephone, in the opinion of the investigator or cannot use an inhalation chamber. * any other reason that makes it impossible to monitor the patient during the study. * enrolled in other clinical trials with unregistered drugs or with registered drugs that may interact with any of the study ips or are contraindicated as concomitant therapy within the last 3 months prior to screening

* blood oxygen saturation level (spo2) \< 94%. * known hypersensitivity to investigational products * chronic treatment with inhaled corticosteroids (up to 30 days) * known history of renal or hepatic failure * abnormal physical examination findings: * respiratory rate \< 25 per minute; * clinical hypotension with associated signs justifying hospital care * feeling unwell for more than 7 days prior to screening. * end-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy \< 3 months. * for any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or intake of concomitant medication proscribed with its use. * patients with known suicidal thoughts, severe psychiatric disorders or major depression that is uncontrolled or controlled by one of the prohibited drugs * known history of long qt syndrome or severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with recovered ventricular fibrillation) * unwilling or unable to comply with the requirements of the study protocol at any time during the study, e.g. no access to or not comfortable with use of a smartphone or with answering questions using a telephone, in the opinion of the investigator or cannot use an inhalation chamber. * any other reason that makes it impossible to monitor the patient during the study. * enrolled in other clinical trials with unregistered drugs or with registered drugs that may interact with any of the study ips or are contraindicated as concomitant therapy within the last 3 months prior to screening

blood oxygen saturation level (spo2) < 94%. known hypersensitivity to investigational products chronic treatment with inhaled corticosteroids (up to 30 days) known history of renal or hepatic failure abnormal physical examination findings: respiratory rate < 25 per minute; clinical hypotension with associated signs justifying hospital care feeling unwell for more than 7 days prior to screening. end-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy < 3 months. for any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or intake of concomitant medication proscribed with its use. patients with known suicidal thoughts, severe psychiatric disorders or major depression that is uncontrolled or controlled by one of the prohibited drugs known history of long qt syndrome or severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with recovered ventricular fibrillation) unwilling or unable to comply with the requirements of the study protocol at any time during the study, e.g. no access to or not comfortable with use of a smartphone or with answering questions using a telephone, in the opinion of the investigator or cannot use an inhalation chamber. any other reason that makes it impossible to monitor the patient during the study. enrolled in other clinical trials with unregistered drugs or with registered drugs that may interact with any of the study ips or are contraindicated as concomitant therapy within the last 3 months prior to screening

blood oxygen saturation level (spo2) < 94%. known hypersensitivity to investigational products chronic treatment with inhaled corticosteroids (up to 30 days) known history of renal or hepatic failure abnormal physical examination findings: respiratory rate < 25 per minute; clinical hypotension with associated signs justifying hospital care feeling unwell for more than 7 days prior to screening. end-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy < 3 months. for any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or intake of concomitant medication proscribed with its use. patients with known suicidal thoughts, severe psychiatric disorders or major depression that is uncontrolled or controlled by one of the prohibited drugs known history of long qt syndrome or severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with recovered ventricular fibrillation) unwilling or unable to comply with the requirements of the study protocol at any time during the study, e.g. no access to or not comfortable with use of a smartphone or with answering questions using a telephone, in the opinion of the investigator or cannot use an inhalation chamber. any other reason that makes it impossible to monitor the patient during the study. enrolled in other clinical trials with unregistered drugs or with registered drugs that may interact with any of the study ips or are contraindicated as concomitant therapy within the last 3 months prior to screening

- blood oxygen saturation level (spo2) < 94%. - known hypersensitivity to investigational products - on-going treatment with telmisartan - chronic treatment with inhaled corticosteroids (up to 30 days) - renal or hepatic failure or known history of renal or hepatic failure - abnormal physical examination findings: - respiratory rate < 25 per minute; - blood pressure < 90/60 mmhg or > 160/100 mmhg; - feeling unwell for more than 7 days prior to screening. - end-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy < 3 months. - for any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or intake of concomitant medication proscribed with its use. - unwilling or unable to comply with the requirements of the study protocol at any time during the study, e.g. no access to or not comfortable with use of a smartphone or with answering questions using a telephone, in the opinion of the investigator or cannot use an inhalation chamber. - any other reason that makes it impossible to monitor the patient during the study.

- blood oxygen saturation level (spo2) < 94%. - known hypersensitivity to investigational products - on-going treatment with telmisartan - chronic treatment with inhaled corticosteroids (up to 30 days) - renal or hepatic failure or known history of renal or hepatic failure - abnormal physical examination findings: - respiratory rate < 25 per minute; - blood pressure < 90/60 mmhg or > 160/100 mmhg; - feeling unwell for more than 7 days prior to screening. - end-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy < 3 months. - for any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or intake of concomitant medication proscribed with its use. - unwilling or unable to comply with the requirements of the study protocol at any time during the study, e.g. no access to or not comfortable with use of a smartphone or with answering questions using a telephone, in the opinion of the investigator or cannot use an inhalation chamber. - any other reason that makes it impossible to monitor the patient during the study.